U.S. Software Stock News

Thinking about what to do with TD SYNNEX stock? You are definitely not alone. The company has quietly turned in a stellar performance, with its share price rising 2.7% in the last week, up nearly 12% over the last month, and soaring an impressive 40.8% year-to-date. Anyone holding since last year has seen a 44.2% return, and the five-year return sits at a remarkable 127.7%. Clearly, something is going right behind the scenes and the market has started to notice. These kinds of numbers do not...

NeoVolta has been making headlines with its recently reported jump in sales, the release of new commercial and industrial energy storage solutions, and an announcement of plans to acquire key assets from Neubau Energy. These moves came after news of the company’s addition to the S&P Global BMI Index, catching the attention of investors looking for growth stories in energy storage. See our latest analysis for NeoVolta. On the heels of its index addition and those recent new product launches,...

BlackRock’s iShares Bitcoin Trust ETF has recently overtaken Deribit as the world’s largest venue for Bitcoin options trading, marking a major shift toward regulated, U.S.-based digital asset markets. This transition reflects a meaningful increase in institutional demand and signals Wall Street’s expanding influence over both spot and derivatives crypto markets. We’ll explore how IBIT’s rapid leadership in the Bitcoin options market cements its evolving role in institutional digital asset...

VisionSys AI (VSA) continues to operate at a loss, but over the past five years, the company has managed to cut its losses by an average of 30.3% per year. While its Price-to-Sales Ratio stands at 1.6x, matching the US Consumer Services industry average and notably lower than the peer group’s 5.8x, there is still no clear sign of profit growth momentum or improvement in net profit margins. Investors are left weighing a steadily improving loss profile and apparently attractive valuation...

AngioDynamics (ANGO) remains unprofitable, with annual losses increasing by 1.3% on average over the last five years. Net profit margins have failed to improve and the company’s earnings quality trails expectations. Looking ahead, the company is tipped to turn profitable within the next three years, with forecast annual earnings growth of 62.02% and revenue set to grow 6.3% per year, even if that is behind the US market’s 9.8% pace. Investors are weighing that aggressive growth outlook...

Thinking about what to do with your Broadridge Financial Solutions shares? It is a common question lately, especially as the stock continues to draw attention from both steady hands and new investors. Broadridge is not your typical, high-volatility tech play, but it still boasts a return of 10.4% over the last year and a staggering 69.0% in the past three years, offering some solid proof of its long-term growth potential. That said, recent momentum has cooled a bit, with the stock down 0.5%...

As the U.S. stock market continues to climb, with major indices like the Dow and S&P 500 setting fresh records despite concerns over a government shutdown, investors are closely watching high-growth sectors such as technology for potential opportunities. In this buoyant environment, identifying promising tech stocks often involves looking at companies that not only show robust growth prospects but also demonstrate resilience in navigating economic uncertainties and evolving market dynamics.

As the U.S. stock market continues its upward trajectory, setting fresh records despite looming government shutdown concerns, investors are increasingly focused on companies with strong growth potential. In this environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those closest to the company’s operations and future prospects.

As U.S. markets continue to rise, with major indices setting fresh records despite concerns over a government shutdown, investors are exploring opportunities beyond the traditional blue-chip stocks. Penny stocks, often seen as relics of past speculative trading days, still hold potential when backed by strong financials and solid business models. These smaller or newer companies can offer unique growth prospects and hidden value for those willing to explore beyond the well-trodden paths of...

If you have been looking at Newell Brands and wondering whether now is the time to buy, hold, or move on, you are definitely not alone. The stock has had a turbulent ride, to say the least. In just the last week, shares crept up by 1.1%, but step back a little and you will find a more sobering story. The stock is down 10.9% over the last month and has lost almost half its value year-to-date. Looking even further back, the drop is even steeper, with a 26.1% decline in the past year and a...

Ellomay Capital (NYSEAM:ELLO) remains unprofitable, with no evidence of a positive net profit margin or high-quality past earnings, but has managed to reduce its losses by an average of 4.7% per year over the past five years. While investors may note the company's progress on trimming losses, ongoing concerns around financial stability and a premium valuation compared to the industry average may weigh on sentiment. See our full analysis for Ellomay Capital. Next, we will see how the latest...

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Kodiak...

Despite an already strong run, Harrow, Inc. ( NASDAQ:HROW ) shares have been powering on, with a gain of 27% in the...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by buying...

Ternium S.A.'s ( NYSE:TX ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong buy right now...

To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...

AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders would be excited to see that the share price has had a great month...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Key Insights The projected fair value for Hexcel is US$107 based on 2 Stage Free Cash Flow to Equity Hexcel is...

It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...

Key Insights Enerpac Tool Group's estimated fair value is US$48.40 based on 2 Stage Free Cash Flow to Equity Current...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

With the business potentially at an important milestone, we thought we'd take a closer look at XOMA Royalty...

In late September 2025, Enanta Pharmaceuticals announced positive topline results from its Phase 2b trial of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults, observing faster symptom resolution and a lower hospitalization rate despite not meeting the trial's primary endpoint. This proof-of-concept success provides the company with clear support to advance zelicapavir into Phase 3 development, potentially addressing significant unmet needs in the RSV market for...